BioFire Warrior Panel Control Kit

K262842 · BioFire Defense, LLC · PMN · Nov 4, 2026 · Microbiology

Device Facts

Record IDK262842
Device NameBioFire Warrior Panel Control Kit
ApplicantBioFire Defense, LLC
Product CodePMN · Microbiology
Decision DateNov 4, 2026
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 866.3920
Device ClassClass 2

Indications for Use

The BioFire Warrior Panel Control Kit contains Positive and Negative External Controls intended for use as assayed quality controls to monitor the performance of in vitro diagnostic laboratory nucleic acid testing procedures for the qualitative detection of Bacillus anthracis, Yersinia pestis, Francisella tularensis, Coxiella burnetii, Ebola virus, Bundibugyo virus, Reston virus, Sudan virus, Tai Forest virus, and orthomarburgviruses (Marburg virus and Ravn virus) when using the BIOFIRE FILMARRAY 2.0 and FILMARRAY TORCH Systems. The BioFire Warrior Panel Control Kit is designed for and intended to be used solely with the BioFire Warrior Panel. This product does not replace manufacturer internal controls provided as part of the BioFire Warrior Panel. Both the Positive and Negative External Controls are provided in a Control Injection Vial format. The Positive Control Injection Vial contains dried synthetic DNA segments in buffer and stabilizer to assess the presence of each individual assay on the BioFire Warrior Panel. The Negative Control Injection Vial is non-reactive with the BioFire Warrior Panel.

Device Story

Kit provides positive and negative external quality controls for BioFire Warrior Panel NAAT assays; monitors amplification, detection, and identification steps. Positive control contains dried synthetic DNA segments in buffer/stabilizer; negative control is non-reactive. Used in clinical laboratory settings by trained personnel. Controls processed via BioFire FilmArray 2.0 or Torch systems; instrument software automatically reports results as 'Detected' or 'Not Detected'. Enables verification of assay performance; ensures reliability of diagnostic results for high-consequence pathogens. Modification from predicate involves increased concentration of nucleic acid in positive control.

Clinical Evidence

No clinical data. Bench testing only. Multi-site reproducibility study performed at three sites using two operators, three FilmArray 2.0 and three Torch instruments, three control lots, and three assay lots over 5 days. Total of 540 replicates (135 per control type per instrument platform). Results showed 100% agreement with expected results (95% CI: 97.2-100.0% for individual controls; 99.3-100.0% overall).

Technological Characteristics

Control Injection Vial format containing dried synthetic DNA segments in buffer and stabilizer. Room temperature storage. Compatible with BIOFIRE FILMARRAY 2.0 and FILMARRAY TORCH systems. Complies with ISO 15223-1 and ISO 14971. No active sensing/actuation; functions as biological/chemical reference material for NAAT assays.

Indications for Use

Indicated for use as external quality control material for laboratory personnel performing nucleic acid testing for B. anthracis, Y. pestis, F. tularensis, C. burnetii, Ebola, Bundibugyo, Reston, Sudan, Tai Forest, and orthomarburgviruses using the BioFire Warrior Panel on FilmArray 2.0 or Torch systems.

Regulatory Classification

Identification

An assayed quality control material for clinical microbiology assays is a device indicated for use in a test system to estimate test precision or to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. This type of device consists of single or multiple microbiological analytes intended for use with either qualitative or quantitative assays.

Special Controls

An assayed quality control material for clinical microbiology assays must comply with the following special controls: (1) Premarket notification submissions must include detailed device description documentation and information concerning the composition of the quality control material, including, as appropriate: (i) Analyte concentration; Expected values: (ii) Analyte source: (iii) (iv) Base matrix; (v) Added components; (vi) Safety and handling information; and, (vii) Detailed instructions for use. (2) Premarket notification submissions must include detailed documentation, including line data as well as detailed study protocols and a statistical analysis plan used to establish performance, including: (i) Description of the process for value assignment and validation. (ii) Description of the protocol(s) used to establish stability. (iii) Line data establishing precision/reproducibility. (iv) Where applicable, assessment of matrix effects and any significant differences between the quality control material and typical patient samples in terms of conditions known to cause analytical error or affect assay performance. (v) Where applicable, identify or define traceability or relationship to a domestic or international standard reference material and/or method. (vi) Where applicable, detailed documentation related to studies for surrogate controls. (3) Premarket notification submissions must include an adequate mitigation (e.g., realtime stability program) to the risk of false results due to potential modifications to the assays specified in the device's 21 CFR 809.10 compliant labeling. (4) Your 21 CFR 809.10 compliant labeling must include the following: (i) The intended use in your 21 CFR 809.10(a)(2) and 21 CFR 809.10(b)(2) compliant labeling must include the following: (A) Assayed control material analyte(s); (B) Whether the material is intended for quantitative or qualitative assays: (C) Stating if the material is a surrogate control; (D)The system(s), instrument(s), or test(s) for which the quality control material is intended. (ii) The intended use in your 21 CFR 809.10(a)(2) and 21 CFR 809.10(b)(2) compliant labeling must include the following statement: "This product is not intended to replace manufacturer controls provided with the device." (iii)A limiting statement that reads "Quality control materials should be used in accordance with local, state, federal regulations, and accreditation requirements."

*Classification.* Class II (special controls). The special controls for this device are:(1) Premarket notification submissions must include detailed device description documentation and information concerning the composition of the quality control material, including, as appropriate: (i) Analyte concentration; (ii) Expected values; (iii) Analyte source; (iv) Base matrix; (v) Added components; (vi) Safety and handling information; and (vii) Detailed instructions for use. (2) Premarket notification submissions must include detailed documentation, including line data as well as detailed study protocols and a statistical analysis plan used to establish performance, including: (i) Description of the process for value assignment and validation. (ii) Description of the protocol(s) used to establish stability. (iii) Line data establishing precision/reproducibility. (iv) Where applicable, assessment of matrix effects and any significant differences between the quality control material and typical patient samples in terms of conditions known to cause analytical error or affect assay performance. (v) Where applicable, identify or define traceability or relationship to a domestic or international standard reference material and/or method. (vi) Where applicable, detailed documentation related to studies for surrogate controls. (3) Premarket notification submissions must include an adequate mitigation (e.g., real-time stability program) to the risk of false results due to potential modifications to the assays specified in the device's 21 CFR 809.10 compliant labeling. (4) Your 21 CFR 809.10 compliant labeling must include the following: (i) The intended use of your 21 CFR 809.10(a)(2) and (b)(2) compliant labeling must include the following: (A) Assayed control material analyte(s); (B) Whether the material is intended for quantitative or qualitative assays; (C) Stating if the material is a surrogate control; and (D) The system(s), instrument(s), or test(s) for which the quality control material is intended. (ii) The intended use in your 21 CFR 809.10(a)(2) and (b)(2) compliant labeling must include the following statement: “This product is not intended to replace manufacturer controls provided with the device.” (iii) A limiting statement that reads “Quality control materials should be used in accordance with local, state, federal regulations, and accreditation requirements.”

Predicate Devices

Submission Summary (Full Text)

{1} [LOGO] FDA U.S. FOOD & DRUG ADMINISTRATION ### 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ### I Background Information: A 510(k) Number K262842 B Applicant BioFire Defense, LLC C Proprietary and Established Names BioFire Warrior Panel Control Kit D Regulatory Information | Product Code | Classification | Regulation Section | Panel | | --- | --- | --- | --- | | PMN | Class II | 21 CFR 866.3920 Assayed quality control material for clinical microbiology assays | MI - Microbiology | ### II Submission/Device Overview: A Purpose for Submission: To obtain substantial equivalence of the BioFire Warrior Panel Control Kit. B Measurand: Multi-analyte external quality control materials for microbiology NAAT assays. C Type of Test: The BioFire Warrior Panel Control Kit contains surrogate assayed quality controls intended to monitor performance of the BioFire Warrior Panel assays. The BioFire Warrior Panel Control Kit includes Positive and Negative Controls provided in a Control Injection Vial format. The Positive External Control contains dried synthetic target DNA sequences in buffer and stabilizer to assess Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 www.fda.gov {2} the presence of each individual assay in the BioFire Warrior Panel. The Negative External Control is non-reactive with the BioFire Warrior Panel. ### III Intended Use/Indications for Use: #### A Intended Use(s): See Indications for Use below. #### B Indication(s) for Use: The BioFire Warrior Panel Control Kit contains Positive and Negative External Controls intended for use as assayed quality controls to monitor the performance of in vitro diagnostic laboratory nucleic acid testing procedures for the qualitative detection of Bacillus anthracis, Yersinia pestis, Francisella tularensis, Coxiella burnetii, Ebola virus, Bundibugyo virus, Reston virus, Sudan virus, Tai Forest virus, and orthomarburgviruses (Marburg virus and Ravn virus) when using the BIOFIRE FILMARRAY 2.0 and FILMARRAY TORCH Systems. The BioFire Warrior Panel Control Kit is designed for and intended to be used solely with the BioFire Warrior Panel. This product does not replace manufacturer internal controls provided as part of the BioFire Warrior Panel. Both the Positive and Negative External Controls are provided in a Control Injection Vial format. The Positive Control Injection Vial contains dried synthetic DNA segments in buffer and stabilizer to assess the presence of each individual assay on the BioFire Warrior Panel. The Negative Control Injection Vial is non-reactive with the BioFire Warrior Panel. For In Vitro Diagnostic Use #### C Special Conditions for Use Statement(s): Rx – For Prescription Use Only #### D Special Instrument Requirements: The BioFire Warrior Panel Control Kit is designed for and intended to be used solely with the BioFire Warrior Panel on BIOFIRE FILMARRAY 2.0 and BIOFIRE FILMARRAY TORCH Systems. ### IV Device/System Characteristics: #### A Device Description: This 510(k) submission supports modifications to the control material previously cleared under K243822 to include a higher concentration of nucleic acid. No other changes were made to the control material. The device description is unchanged from the prior clearance. #### B Principle of Operation: K262842 - Page 2 of 6 {3} Each positive or negative control included in the BioFire Warrior Panel Control Kit is processed separately, according to the assay manufacturer's Instructions for Use, and monitors the detection and identification of the organisms detected by the BioFire Warrior Panel. Results are reported automatically by instrument software as either "Detected" or "Not Detected" (Table 1). Table 1. Expected Results for the BioFire Warrior Panel Control Kit | BioFire Warrior Panel Analyte | Positive External Control Result | Negative External Control Result | | --- | --- | --- | | **Bacteria** | | | | *Bacillus anthracis* | Detected | Not Detected | | *pXO1* | Detected | Not Detected | | *pXO2* | Detected | Not Detected | | *Coxiella burnetii* | Detected | Not Detected | | *Francisella tularensis* | Detected | Not Detected | | *Yersinia pestis* | Detected | Not Detected | | **Viruses** | | | | Bundibugyo virus | Detected | Not Detected | | Tai Forest virus | Detected | Not Detected | | Reston virus | Detected | Not Detected | | Sudan virus | Detected | Not Detected | | Ebola virus | Detected | Not Detected | | Orthomarburgviruses | Detected | Not Detected | # V Substantial Equivalence Information: A Predicate Device Name(s): BioFire Warrior Panel Control Kit B Predicate 510(k) Number(s): K243822 C Comparison with Predicate(s): | Device & Predicate Device(s): | Device: K262842 | Predicate: K243822 | | --- | --- | --- | | Device Trade Name | BioFire Warrior Panel Control Kit | BioFire Warrior Panel Control Kit | | **General Device Characteristic Similarities** | | | | Intended Use/ Indications For Use | The BioFire Warrior Panel Control Kit contains Positive and Negative External Controls intended for use as assayed quality controls to | The BioFire Warrior Panel Control Kit contains Positive and Negative External Controls intended for use as assayed | K262842 - Page 3 of 6 {4} | | monitor the performance of in vitro diagnostic laboratory nucleic acid testing procedures for the qualitative detection of *Bacillus anthracis*, *Yersinia pestis*, *Francisella tularensis*, *Coxiella burnetii*, Ebola virus, Bundibugyo virus, Reston virus, Sudan virus, Tai Forest virus, and orthomarburgviruses (Marburg virus and Ravn virus) when using the BIOFIRE FILMARRAY 2.0 and FILMARRAY TORCH Systems. The BioFire Warrior Panel Control Kit is designed for and intended to be used solely with the BioFire Warrior Panel. This product does not replace manufacturer internal controls provided as part of the BioFire Warrior Panel. Both the Positive and Negative External Controls are provided in a Control Injection Vial format. The Positive Control Injection Vial contains dried synthetic DNA segments in buffer and stabilizer to assess the presence of each individual assay on the BioFire Warrior Panel. The Negative Control Injection Vial is non-reactive with the BioFire Warrior Panel. | quality controls to monitor the performance of in vitro diagnostic laboratory nucleic acid testing procedures for the qualitative detection of *Bacillus anthracis*, *Yersinia pestis*, *Francisella tularensis*, *Coxiella burnetii*, Ebola virus, Bundibugyo virus, Reston virus, Sudan virus, Tai Forest virus, and orthomarburgviruses (Marburg virus and Ravn virus) when using the BIOFIRE FILMARRAY 2.0 and FILMARRAY TORCH Systems. The BioFire Warrior Panel Control Kit is designed for and intended to be used solely with the BioFire Warrior Panel. This product does not replace manufacturer internal controls provided as part of the BioFire Warrior Panel. Both the Positive and Negative External Controls are provided in a Control Injection Vial format. The Positive Control Injection Vial contains dried synthetic DNA segments in buffer and stabilizer to assess the presence of each individual assay on the BioFire Warrior Panel. The Negative Control Injection Vial is non-reactive with the BioFire Warrior Panel. | | --- | --- | --- | | **Physical Format** | Same | Control Injection Vial | | **Controls Included** | Same | Six (6) Positive Controls and six (6) Negative Controls | | **Assay Steps Monitored** | Same | Amplification, detection, identification | | **Reagent Storage** | Same | Room temperature | | **Test System** | Same | BIOFIRE FILMARRAY 2.0 or BIOFIRE FILMARRAY TORCH Systems | | **General Device Characteristic Differences** | | | | **Composition** | Dried synthetic DNA segments with | Dried synthetic DNA segments | K262842 - Page 4 of 6 {5} | | equivalent or higher concentration than the predicate device | | | --- | --- | --- | ## VI Standards/Guidance Documents Referenced: ISO 15223-1 Fourth edition 2021-07 5-134, Medical devices – Symbols to be used with information to be supplied by the manufacturer – Part 1: General requirements. ISO 14971 Third Edition 2019-12 5-125, Medical devices – Application of risk management to medical devices. CLSI EP25 2 \( ^{nd} \) Edition Evaluation of Stability of In Vitro Medical Laboratory Test Reagents. ## VII Performance Characteristics (if/when applicable): ### A Analytical Performance: #### 1. Precision/Reproducibility: A multi-site reproducibility study was conducted for the BioFire Warrior Panel Control Kit. Testing was performed at three sites. At each site, testing was performed by two operators using three FilmArray 2.0 and three Torch instruments, three BioFire Warrior Panel Control Kit lots, and three BioFire Warrior Panel kit lots. Testing took place over 5 days at each site. This generated 135 replicates for the Positive Control and 135 replicates for the Negative Control on the FilmArray 2.0, and 135 replicates for the Positive Control and 135 replicates for the Negative Control on the FilmArray Torch. Reproducibility was evaluated by comparing the observed results to the expected results for each control type. The percent agreement between the observed and expected test results for the Positive and Negative Controls per test site, instrument, and overall are shown in Table 2. Table 2. Reproducibility Results | Control Type | Expected Result | Observed/Expected (Percent Agreement) [95% Confidence Interval] | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | FilmArray 2.0 | | | | FilmArray Torch | | | | | | | Site 1 | Site 2 | Site 3 | All Sites | Site 1 | Site 2 | Site 3 | All Sites | | Positive | Passed\( ^{1} \) | 45/45100% | 45/45100% | 45/45100% | 135/135100%[97.2-100.0%] | 45/45100% | 45/45100% | 45/45100% | 135/135100%[97.2-100.0%] | | Negative | Passed\( ^{2} \) | 45/45100% | 45/45100% | 45/45100% | 135/135100%[97.2-100.0%] | 45/45100% | 45/45100% | 45/45100% | 135/135100%[97.2-100.0%] | | Overall Agreement with Expected Result | | 540/540100%[99.3-100.0%] | | | | | | | | \( ^{1} \) All BioFire Warrior Panel assays are positive. \( ^{2} \) All BioFire Warrior Panel assays are negative. #### 2. Linearity: Not applicable. K262842 - Page 5 of 6 {6} 3. Analytical Specificity/Interference: Not applicable. 4. Detection Limit and Assay Reportable Range: Not applicable. 5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods): Not applicable. 6. Assay Cut-Off: Not applicable. # **B Comparison Studies:** Not applicable. # **C Clinical Studies:** 1. Clinical Sensitivity: Not applicable. 2. Clinical Specificity: Not applicable. 3. Clinical Cut-Off Not applicable. 4. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable. # **D Expected Values/Reference Range:** The BioFire Warrior Panel Control Kit is a qualitative control and the expected results for BioFire Warrior Panel are listed in Table 1 above. # **VIII Proposed Labeling:** The labeling supports the finding of substantial equivalence for this device. # **IX Conclusion:** K262842 - Page 6 of 6 {7} The submitted information in this premarket notification is complete and supports a substantial equivalence decision. K262842 - Page 7 of 6
Innolitics
Guidance Recalls

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...